Single-cell analysis unravels divergent gene signatures shaping seminoma stemness and metastasis
本研究通过单细胞RNA测序分析揭示了精原细胞瘤的转移机制，识别出关键基因DPPA4和PSMA7，这些基因在维持肿瘤干性和促进转移中发挥重要作用。研究结果为精准医学提供了重要的分子标志物，有助于患者风险分层，推动个性化治疗策略的发展。
Atypical intraductal proliferation in prostate biopsy — a diagnostic grey zone with clinical implications
Atypical intraductal proliferation (AIP) is identified as a critical diagnostic grey zone in prostate biopsies, indicating a potential risk for aggressive prostate cancer. The study highlights that AIP often coexists with intermediate-risk prostate cancer and shares molecular characteristics with intraductal carcinoma, suggesting its role in risk stratification. The findings advocate for enhanced precision diagnostics and active surveillance strategies in prostate cancer management.
Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer
该研究评估了trastuzumab deruxtecan（T-DXd）在HR阴性HER2低表达转移性乳腺癌患者中的真实世界疗效，结果显示客观反应率为35.9%，疾病控制率为75%。研究还识别了高风险亚组和潜在的抗药性生物标志物，提供了对治疗决策的指导。这些发现为该领域的临床实践提供了重要的证据支持，具有显著的商业价值。
Pre-rRNAs control mitosis by maintaining chromosomal segregation through protecting SMC2 from AURKA-mediated phosphorylation
本研究揭示了前rRNA在有丝分裂中的重要作用，特别是通过保护SMC2免受AURKA介导的磷酸化，从而维持染色体的正常分离。研究表明，前rRNA的缺失会导致有丝分裂灾难，进而影响细胞的基因组稳定性。这一发现为癌症治疗提供了新的靶点，具有重要的商业潜力。
EGR4 transcriptionally upregulates GDF15 to promote gastric cancer metastasis
本研究揭示了EGR4/GDF15轴在胃癌转移中的关键作用，EGR4通过转录激活GDF15促进癌细胞迁移和转移。研究表明，高表达的EGR4与胃癌患者的生存率降低相关，且EGR4可通过GDF15激活ErbB3/ErbB1信号通路，促进肿瘤微环境中的癌相关成纤维细胞（CAFs）活化，从而增强癌细胞的迁移能力。这一发现为胃癌转移的靶向治疗提供了新的思路。
Single-cell RNA sequencing identifies potential critical prognostic biomarkers in bladder carcinoma
本研究利用单细胞RNA测序技术，识别出膀胱癌患者的关键预后生物标志物，建立了基于LASSO-Cox回归的风险模型，以有效预测患者生存率。研究发现，IGFBP5、KRT14和SERPINF1等基因在膀胱癌细胞中表达显著升高，并与患者预后密切相关。这些发现为膀胱癌的个性化治疗和预后评估提供了重要的生物标志物，具有潜在的临床应用价值。
TRIM11 potentiates antitumor immunity via inhibition of the IFN-γ/PD-L1 axis
TRIM11作为E3泛素连接酶，通过抑制IFN-γ诱导的PD-L1表达，增强肿瘤微环境中的抗肿瘤免疫。研究表明，TRIM11的低表达与患者预后不良相关，且可能预测对免疫检查点抑制疗法的敏感性。这一发现为癌症免疫治疗提供了新的潜在靶点，具有重要的临床应用价值。
The RNA N6-methyladenosine methylome coordinates long non-coding RNAs to mediate cancer drug resistance by activating PI3K signaling
该研究探讨了RNA N6-甲基腺苷(m6A)修饰如何通过调控长非编码RNA(lncRNA)介导癌症药物耐药性，尤其是在慢性髓性白血病(CML)中。研究发现，特定lncRNA的上调与对酪氨酸激酶抑制剂(TKI)的耐药性相关，并且通过激活PI3K信号通路促进耐药细胞的生长。该发现为CML患者提供了新的预后指标和潜在的治疗靶点，尤其是针对不携带BCR-ABL突变的耐药患者。
SETD7-mediated H3K4me1 activates ALDH1A3 to drive ferroptosis resistance in esophageal squamous cell carcinoma
SETD7, a histone lysine methyltransferase, is significantly overexpressed in esophageal squamous cell carcinoma (ESCC) and correlates with clinical staging. This study demonstrates that SETD7 promotes ESCC cell proliferation and migration while enhancing resistance to ferroptosis through H3K4me1-mediated activation of ALDH1A3. The findings suggest that targeting SETD7 could provide a novel therapeutic strategy for ESCC, a cancer with poor prognosis and limited treatment options.
MDMX reprograms glycolysis of hepatocellular carcinoma via 14-3-3γ/FOXO1
MDMX plays a crucial role in hepatocellular carcinoma (HCC) by promoting glycolysis through the degradation of FOXO1, a key tumor suppressor. The study demonstrates that MDMX is overexpressed in HCC tissues, correlating with poor patient prognosis, particularly in those with mutant p53. Mechanistically, MDMX enhances the interaction between FOXO1 and 14-3-3γ, leading to FOXO1 degradation and subsequent metabolic reprogramming. These findings suggest that targeting MDMX could provide new therapeutic strategies for HCC treatment.
The transcription factor ZEB2 mediates the antitumor efficacy of tumor-infiltrating lymphocytes in non–small cell lung cancer
ZEB2作为转录因子，在非小细胞肺癌中发挥重要作用，促进CD8+ T细胞的抗肿瘤效应。研究表明，ZEB2通过调控T-bet的表达，影响CD8+ T细胞的分化，可能为免疫治疗提供新的靶点。该研究基于对14名未接受治疗的非小细胞肺癌患者的单细胞RNA测序分析，揭示了ZEB2在肿瘤微环境中的关键作用，具有重要的临床应用潜力。
Pregnane X receptor protects against age-related bone loss in males via PI3K/Akt-mediated inhibition of apoptosis
本研究揭示孕烯X受体(Pxr)在维持骨骼稳态中的关键作用。Pxr缺失导致小鼠出现骨质疏松表型，表现为骨密度降低和骨生成抑制。通过RNA测序，发现Pxr缺失抑制了PI3K/Akt信号通路，导致细胞凋亡和炎症反应增加。相反，Pxr的过表达或激动剂的应用能够改善老年小鼠的骨质量，表明Pxr可能成为治疗年龄相关骨质疏松的新靶点。
Profilin-2 promotes tumour aggressiveness in oral squamous cell carcinoma via HDAC1 modulation: implications for EMT and targeted therapy
PFN2在口腔鳞状细胞癌中被发现是一个重要的肿瘤进展驱动因子，其高表达与淋巴结转移及较差的生存率相关。研究显示PFN2通过调节HDAC1影响细胞增殖和转移，且对HDAC抑制剂SAHA表现出敏感性，提示其在靶向治疗中的潜在应用价值。
Targeting the ac4C ‘Writer’ NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumor cells
NAT10在胰腺癌中发挥关键作用，通过调节ETS2和KRT8的mRNA稳定性促进肿瘤生长和免疫逃逸。研究表明，NAT10的抑制结合抗PD-L1治疗可显著增强抗肿瘤免疫反应，提供了新的治疗策略以克服胰腺癌的免疫抑制微环境。
Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations
本研究探讨了FGFR扩增的HR+乳腺癌患者在CDK4/6抑制剂治疗后的联合治疗策略，使用rogaratinib、fulvestrant和palbociclib。结果表明，生物标志物驱动的治疗策略在PIK3CA和ESR1野生型患者中显示出显著的进展无生存期(PFS)改善。该研究为FGFR靶向治疗提供了新的临床证据，强调了在早期研发阶段的投资潜力。